Cerulean Pharma Appoints Chief Business Officer January 23 2012

Cerulean Pharma Inc., a leader in designing and developing tumor-targeted nanopharmaceuticals, today announced the appointment of Chris Guiffre as Senior Vice President and Chief Business Officer, a newly created position.

view full story

FORMA Therapeutics Announces Drug Discovery Alliance With Janssen Biotech January 10 2012

FORMA Therapeutics today announced an exclusive alliance with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies, in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms.

view full story

Hydra Biosciences and Cubist Pharmaceuticals Announce Plans to Initiate Phase 1 Trial for Novel TRPA1 Modulator January 10 2012

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Hydra Biosciences, Inc. today announced plans to begin a Phase 1 clinical trial for a small molecule antagonist of the human Transient Receptor Potential Ankyrin repeat 1 (TRPA1) ion channel discovered in a collaboration between Cubist and Hydra.

view full story

Sutro Biopharma Announces Newly Formed Scientific Advisory Board January 07 2012

Sutro Biopharma appointed James A. Wells, Ph.D., who has a depth of expertise and defining experience in protein engineering, and James R. Swartz, Sc.D., a leading expert in the field of cell-free protein synthesis, to the Sutro Scientific Advisory Board. Dr. Wells will serve as Chairman of the SAB

view full story

FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim January 05 2012

FORMA Therapeutics announced a research and development collaboration with Boehringer Ingelheim to discover and develop novel drug candidates for the treatment of cancer.

view full story

Viamet Initiates Phase 1 Prostate Cancer Clinical Trial January 04 2012

Viamet Pharmaceuticals, Inc., announced that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer (CRPC). VT-464 is a novel, non-steroidal, small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile® Technology.

view full story

Receptos and Ono Establish Collaboration on Bioactive Lipid Discovery Research December 12 2011

Receptos Inc. announced the establishment of a collaboration with Ono Pharmaceutical Co., Ltd. (Osaka, Japan) for the research and development of small molecule modulators of an undisclosed G–protein coupled receptor (GPCR) target. Under the terms of the agreement, Receptos will use its proprietary technology platform to produce high resolution protein crystal structures of the discovery target and drive Ono’s structure–based drug design efforts.

view full story

Aileron Announces Expansion of Roche Collaboration November 16 2011

Aileron Therapeutics, Inc. announced the expansion of an existing drug discovery collaboration with Roche adding a third target in inflammatory disease to the existing oncology targets.

view full story

Cerulean Pharma Presents Phase 1/2a Lung Cancer Clinical Study of CRLX101 November 14 2011

Cerulean Pharma presented final data from the non-small cell lung cancer Phase 1/2a clinical study of CRLX101 at the AACR-NCI-EORTC conference. The drug was well tolerated at the maximum tolerated dose (MTD) and provided encouraging progression free survival (PFS) times.

view full story

Viamet Appoints Chief Medical Officer November 03 2011

Viamet Pharmaceuticals Appoints Former Novartis Executive Marc Rudoltz, M.D. as Chief Medical Officer.

view full story

pages:   1  - 2  - 3  - 4